Clinical Neuroradiology, Journal Year: 2024, Volume and Issue: 34(1), P. 33 - 43
Published: Jan. 26, 2024
Language: Английский
Genes, Journal Year: 2022, Volume and Issue: 13(5), P. 851 - 851
Published: May 10, 2022
Clear cell renal carcinoma (ccRCC) is the most prevalent subtype of carcinoma, which characterized by metabolic reprogramming. Cuproptosis, a novel form death, highly linked to mitochondrial metabolism and mediated protein lipoylation. However, clinical impacts cuproptosis-related genes (CRGs) in ccRCC largely remain unclear. In current study, we systematically evaluated genetic alterations ccRCC. Our results revealed that CDKN2A, DLAT, DLD, FDX1, GLS, PDHA1 PDHB exhibited differential expression between normal tissues (|log2(fold change)| > 2/3 p < 0.05). Utilizing an iterative sure independence screening (SIS) method, separately constructed prognostic signature CRGs for predicting overall survival (OS) progression-free (PFS) patients. The score yielded area under curve (AUC) 0.658 0.682 prediction 5-year OS PFS, respectively. Kaplan−Meier analysis OS, higher risk gene was significantly correlated with worse (HR = 2.72 (2.01−3.68), log-rank 1.76 × 10−7). Patients had shorter PFS 2.83 (2.08−3.85), 3.66 Two independent validation datasets (GSE40435 (N 101), GSE53757 72)) were collected meta-analysis, suggesting CDKN2A (log2(fold change) 1.46, 95%CI: 1.75−2.35) showed while DLAT −0.54, −0.93−−0.15) FDX1 −1.01, −1.61−−0.42) lowly expressed. also associated immune infiltration levels programmed death 1 (PD-1) (CDKN2A: r 0.24, 2.14 10−8; FDX1: −0.17, 1.37 10−4). conclusion, could serve as potential predictor patients may offer insights into cancer treatment.
Language: Английский
Citations
261
npj Precision Oncology, Journal Year: 2024, Volume and Issue: 8(1)
Published: March 29, 2024
Abstract This review delves into the most recent advancements in applying artificial intelligence (AI) within neuro-oncology, specifically emphasizing work on gliomas, a class of brain tumors that represent significant global health issue. AI has brought transformative innovations to tumor management, utilizing imaging, histopathological, and genomic tools for efficient detection, categorization, outcome prediction, treatment planning. Assessing its influence across all facets malignant management- diagnosis, prognosis, therapy- models outperform human evaluations terms accuracy specificity. Their ability discern molecular aspects from imaging may reduce reliance invasive diagnostics accelerate time diagnoses. The covers techniques, classical machine learning deep learning, highlighting current applications challenges. Promising directions future research include multimodal data integration, generative AI, large medical language models, precise delineation characterization, addressing racial gender disparities. Adaptive personalized strategies are also emphasized optimizing clinical outcomes. Ethical, legal, social implications discussed, advocating transparency fairness integration neuro-oncology providing holistic understanding impact patient care.
Language: Английский
Citations
52
Genes, Journal Year: 2024, Volume and Issue: 15(4), P. 501 - 501
Published: April 17, 2024
Glioblastoma, the most aggressive and common malignant primary brain tumour, is characterized by infiltrative growth, abundant vascularization, clinical evolution. Patients with glioblastoma often face poor prognoses, a median survival of approximately 15 months. Technological progress subsequent improvement in understanding pathophysiology these tumours have not translated into significant achievements therapies or outcomes for patients. Progress molecular profiling has yielded new omics data more refined classification glioblastoma. Several typical genetic epigenetic alterations include mutations genes regulating receptor tyrosine kinase (RTK)/rat sarcoma (RAS)/phosphoinositide 3-kinase (PI3K), p53, retinoblastoma protein (RB) signalling, as well mutation isocitrate dehydrogenase (IDH), methylation O6-methylguanine-DNA methyltransferase (MGMT), amplification epidermal growth factor vIII, codeletion 1p/19q. Certain microRNAs, such miR-10b miR-21, also been identified prognostic biomarkers. Effective treatment options are limited. Surgery, radiotherapy, alkylating agent chemotherapy remain pillars treatment. Only promoter gene MGMT predicts benefit from temozolomide it guides choice first-line elderly targeted strategies based on tumour-intrinsic dominant signalling pathways antigenic tumour profiles under investigation trials. This review explores potential biomarkers that could be deployed analytical tools diagnosis prognostication Recent advancements treating discussed, along liquid biopsies to advance personalized medicine field glioblastoma, highlighting challenges promises future.
Language: Английский
Citations
17
International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(13), P. 7474 - 7474
Published: July 5, 2022
Glioblastoma is the most aggressive malignant tumor of central nervous system with a low survival rate. The difficulty obtaining this material represents major limitation, making real-time monitoring progression difficult, especially in events recurrence or resistance to treatment. identification characteristic biomarkers indispensable for an accurate diagnosis, rigorous follow-up patients, and development new personalized treatments. Liquid biopsy, as minimally invasive procedure, holds promise regard. purpose paper summarize current literature regarding molecular circulating glioblastoma importance their integration valuable tool improve patient care.
Language: Английский
Citations
40
Sensors, Journal Year: 2023, Volume and Issue: 23(24), P. 9842 - 9842
Published: Dec. 15, 2023
Gliomas, a prevalent category of primary malignant brain tumors, pose formidable clinical challenges due to their invasive nature and limited treatment options. The current therapeutic landscape for gliomas is constrained by "one-size-fits-all" paradigm, significantly restricting efficacy. Despite the implementation multimodal strategies, survival rates remain disheartening. conventional approach, involving surgical resection, radiation, chemotherapy, grapples with substantial limitations, particularly in addressing gliomas. Conventional diagnostic tools, including computed tomography (CT), magnetic resonance imaging (MRI), positron emission (PET), play pivotal roles outlining tumor characteristics. However, they face such as poor biological specificity distinguishing active regions. ongoing development tools approaches represents multifaceted promising frontier battle against this challenging tumor. aim comprehensive review address recent advances These innovations minimize invasiveness while enabling precise, targeting localized Researchers are actively developing new colorimetric techniques, electrochemical biosensors, optical coherence tomography, reflectometric interference spectroscopy, surface-enhanced Raman biosensors. regulate progression develop precise methods Recent technological advancements, coupled bioelectronic sensors, open avenues modalities, minimizing unprecedented precision. next generation strategies holds potential precision medicine, aiding early detection effective management solid tumors. offer promise adopting medicine methodologies, disease detection, improving management. This comprehensively recognizes critical role pioneering interventions, holding significant revolutionize therapeutics.
Language: Английский
Citations
37
Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13
Published: July 6, 2023
Glioblastoma (GBM), the most lethal primary brain malignancy, is divided into histological (hist-GBM) and molecular (mol-GBM) subtypes according to 2021 World Health Organization classification of central nervous system tumors. This study aimed characterize clinical, radiological, molecular, survival features GBM under current scheme explore determinants.We re-examined genetic alterations IDH-wildtype diffuse gliomas at our institute from 2011 2022, enrolled GBMs for analysis after re-classification. Univariable multivariable analyses were used identify determinants.Among 209 gliomas, 191 GBMs, including 146 hist-GBMs (76%) 45 mol-GBMs (24%). Patients with younger, less likely develop preoperative motor dysfunction, more epilepsy than hist-GBMs. Mol-GBMs exhibited lower radiographic incidences contrast enhancement intratumoral necrosis. Common included copy-number changes in chromosomes 1, 7, 9, 10, 19, as well EGFR, TERT, CDKN2A/B, PTEN, distinct patterns observed between two subtypes. The median overall (mOS) GMB was 12.6 months. had a higher mOS hist-GBMs, although not statistically significant (15.6 vs. 11.4 months, p=0.17). Older age, male sex, tumor involvement deep structure or functional area, CDK4, CDK6, CIC, FGFR3, KMT5B, MYB predictors worse prognosis, while MGMT promoter methylation, maximal resection, treatment based on Stupp protocol predictive better survival.The definition its prognostic characteristics have been altered classification.
Language: Английский
Citations
26
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 11, 2024
Glioma is the most common primary brain tumor, characterized by a consistently high patient mortality rate and dismal prognosis affecting both survival quality of life. Substantial evidence underscores vital role immune system in eradicating tumors effectively preventing metastasis, underscoring importance cancer immunotherapy which could potentially address challenges glioma therapy. Although immunotherapies have shown promise preclinical early-phase clinical trials, they face specific limitations that hindered their success further phase III trials. Resistance to therapy has been major challenge across many experimental approaches, as now, no approved. In addition, there are several other facing such intra- inter-tumoral heterogeneity, an inherently immunosuppressive microenvironment, unique tissue-specific interactions between central nervous peripheral system, existence blood-brain barrier, physical barrier drug delivery, effects standard Therefore, this review, we delve into need be addressed achieve boosted against gliomas. First, discuss hurdles posed particularly its cellular inhabitants, particular tumor-associated microglia macrophages (TAMs), myeloid cells, represent significant effective immunotherapy. Here emphasize impact inducing immunogenic cell death (ICD) on migration Th17 cells tumor converting it immunologically “hot” environment enhancing effectiveness ongoing Next, associated with accurate identification characterization profiles gliomas, implications for prognosis, can facilitate selection personalized treatment regimens predict patient’s response Finally, explore prospective approach developing highly vaccination strategies based search patient-specific neoantigens. All pertinent discussed review will serve compass future developments immunotherapeutic paving way upcoming research endeavors.
Language: Английский
Citations
13
Biomedicines, Journal Year: 2024, Volume and Issue: 12(2), P. 375 - 375
Published: Feb. 6, 2024
Research on the development of photodynamic therapy for treatment brain tumors has shown promise in this highly aggressive form cancer. Analysis both vivo studies and clinical shows that can provide significant benefits, such as an improved median rate survival. The use is characterized by relatively few side effects, which a advantage compared to conventional methods often-used tumor surgery, advanced radiotherapy, classic chemotherapy. Continued research area could bring advances, influencing future standards difficult deadly disease.
Language: Английский
Citations
11
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: July 26, 2024
Cancer remains a global health challenge, necessitating continuous advancements in diagnostic and treatment strategies. This review focuses on the utility of non-invasive biomarkers cancer diagnosis treatment, their role early detection, disease monitoring, personalized therapeutic interventions. Through systematic literature, we identified 45 relevant studies that highlight potential these across various types, such as breast, prostate, lung, colorectal cancers. The discussed include liquid biopsies, epigenetic markers, non-coding RNAs, exosomal cargo, metabolites. Notably, particularly those based circulating tumour DNA (ctDNA), have emerged most promising method for early, detection due to ability provide comprehensive genetic information from easily accessible blood samples. demonstrates how can facilitate accurate subtyping, tailored strategies, thereby improving patient outcomes. It underscores transformative oncology, highlighting application enhancing survival rates, precision care.
Language: Английский
Citations
11
BJC Reports, Journal Year: 2024, Volume and Issue: 2(1)
Published: April 19, 2024
Glioblastoma (GB) is a lethal and aggressive brain tumour. While molecular characteristics of GB studied extensively, the aetiology remains uncertain. The interest in exploring viruses as potential contributor to development stems from notion that are known play key role pathogenesis other human cancers such cervical cancer. Nevertheless, controversial.
Language: Английский
Citations
8